Therapeutic Classification

low molecular weight heparin Registry

Clinical reference for low molecular weight heparin medications. Access safety monographs, dosing adjustments, and drug-drug interactions for all registered brand names and generics in this class.

Registered Medications (low molecular weight heparin)

Medication	Therapeutic Class	Maternal Safety
Enoxaparin Standard of care for VTE prevention and treatment in pregnancy. Does not cross the placenta due to its large molecular weight. No teratogenicity. Requires dose adjustment in pregnancy (weight-based; anti-Xa monitoring in some cases). Renal function monitoring recommended. Switch to unfractionated heparin (UFH) at 36–37 weeks to allow neuraxial anesthesia planning.	Low Molecular Weight Heparin	safe
ENOXAPARIN SODIUM Other drugs that affect hemostasis increase bleeding risk Can cause spinal or epidural hematoma leading to paralysis with neuraxial anesthesia.	Low Molecular Weight Heparin	safe
ENOXAPARIN SODIUM (PRESERVATIVE FREE) Other drugs that affect hemostasis increase bleeding risk Can cause spinal or epidural hematoma leading to paralysis with neuraxial anesthesia.	Low Molecular Weight Heparin	safe

This therapeutic registry is dynamically synthesized from professional clinical sources. Listing of a medication does not imply equivalence; refer to individual monographs for head-to-head pharmacological data.